Overview

A Study of KRN23 in X-linked Hypophosphatemia

Status:
Completed

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the safety and tolerability of KRN23 after a single intravenous (IV) and subcutaneous (SC) administration in XLH patients.

Phase:

Phase 1

Details

Lead Sponsor:

Kyowa Hakko Kirin Pharma, Inc.